The NADP Foundation expects to fund two to three projects in 2025 with a maximum award of $50,000 for each project. The proposals are due Oct. 1, and the Foundation expects to announce awards on Dec.

– On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/refractory AL Amyloidosis – ...

SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, ...

RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath. Four active cancer cent ...

The Company also announced that its management team plans to present and meet with investors at the following upcoming investor conferences: ...

– Company to Host Conference Call on August 13, 2025, at 4:30 p.m. ET – ...

In addition, Fractyl granted the underwriters a 30-day option to purchase up to an additional 2,857,142 shares of common stock, along with associated Tranche A and Tranche B Warrants, at the public ...

A live webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days ...

Additional information about the reverse stock split can be found in the definitive proxy statement filed with the Securities and Exchange Commission (SEC) on June 10, 2025, which is available on the ...

TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- As Ontario commits $1.8 billion to expand access to team-based primary care, the Lung Health Foundation (LHF) is calling on the government to take a vital ...

FDA response expected within six weeks; Company remains focused on 2025 U.S. expansion. NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ( ...

NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C.